GO:0017059 serine palmitoyltransferase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017059 defines the serine palmitoyltransferase (SPT) complex, the enzyme that catalyzes the first and rate-limiting step of sphingolipid biosynthesis.
• The eukaryotic SPT complex is a multiprotein assembly in the endoplasmic reticulum (ER) membrane, consisting of catalytic subunits (SPTLC1, SPTLC2, SPTLC3) and regulatory subunits (SPTSSA/SPTSSB activators, ORMDL1/2/3 inhibitors).
• SPTLC3 is a catalytically active subunit that regulates plasma membrane sphingolipid composition and is essential for complex I activity in mitochondria.
• The SPT complex localizes to ER-mitochondria contact sites, linking sphingolipid synthesis to mitochondrial function and cellular metabolism.
• Dysregulation of SPT complex components is implicated in human diseases including macular degeneration, peripheral neuropathy, asthma, and ischemic cardiomyopathy.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect SPT subunit functions and their roles in disease.
Description
The serine palmitoyltransferase (SPT) complex, defined by the Gene Ontology term GO:0017059, is a protein complex that catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the first committed step in sphingolipid biosynthesis. This reaction is rate-limiting for the production of all sphingolipids, a diverse class of lipids essential for membrane structure, signaling, and cellular homeostasis. In eukaryotes, the SPT complex is a multiprotein assembly localized to the endoplasmic reticulum (ER) membrane, comprising catalytic subunits (SPTLC1, SPTLC2, and SPTLC3 in humans) and regulatory components such as activators (SPTSSA/SPTSSB) and negative regulators (ORMDL1/2/3). In bacteria, the enzyme functions as a cytoplasmic homodimer, highlighting evolutionary divergence in complex organization. Research on the SPT complex has gained momentum due to its central role in sphingolipid metabolism and its links to human diseases. For example, SPTLC3 is essential for mitochondrial complex I activity and contributes to ischemic cardiomyopathy, and it regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis. The complex also assembles at ER-mitochondria contact sites, integrating lipid synthesis with mitochondrial function. Dysregulation of SPT components has been associated with macular disease and peripheral neuropathy, asthma, and immune cell exocytosis. Understanding the structure, regulation, and function of the SPT complex is therefore critical for both basic cell biology and therapeutic development. This article provides a comprehensive overview of GO:0017059, covering its definition, subunit composition, molecular mechanism, regulatory mechanisms, disease associations, and experimental approaches including CRISPR-based models. All statements are grounded in published literature and the QuickGO definition.
serine palmitoyltransferase complex At A Glance
| GO ID | GO:0017059 |
|---|---|
| GO term | serine palmitoyltransferase complex |
| Ontology | cellular_component |
| Synonym | serine C-palmitoyltransferase complex; serine palmitoyltransferase; Orm1/2, Tsc3 and Sac1 complex; SPOTS complex; SPT |
| Major function | Catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the first and rate-limiting step in sphingolipid biosynthesis |
| Cellular localization | Endoplasmic reticulum membrane in eukaryotes; cytoplasm in bacteria |
| Subunit composition | Catalytic subunits: SPTLC1, SPTLC2, SPTLC3 (humans); LCB1, LCB2 (S. cerevisiae). Regulatory subunits: SPTSSA/SPTSSB activators, ORMDL1/2/3 inhibitors (humans); TSC3 activator, ORM1/2 inhibitors (S. cerevisiae) |
| Evolutionary conservation | Bacterial homodimer vs. eukaryotic multiprotein complex |
What Is GO:0017059?
GO:0017059 (serine palmitoyltransferase complex) is a protein complex that catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the sphingoid base that serves as the starting point for all sphingolipids. In bacteria, the enzyme is a cytoplasmic homodimer, whereas in eukaryotes it is a multiprotein complex localized to the endoplasmic reticulum. The eukaryotic complex consists of catalytic components (SPTLC1, SPTLC2, and SPTLC3 in humans; LCB1 and LCB2 in S. cerevisiae) and regulatory components, including activators (SPTSSA/SPTSSB in humans, TSC3 in S. cerevisiae) and negative regulators (ORMDL1/ORMDL2/ORMDL3 in humans, ORM1/2 in S. cerevisiae). Synonyms include serine C-palmitoyltransferase complex, serine palmitoyltransferase, Orm1/2, Tsc3 and Sac1 complex, SPOTS complex, and SPT.
Why Is serine palmitoyltransferase complex Important in Cell Biology?
The serine palmitoyltransferase complex is fundamentally important because it catalyzes the first and rate-limiting step of sphingolipid biosynthesis, a pathway that produces essential membrane lipids and signaling molecules. Sphingolipids are critical for membrane integrity, cell signaling, and organelle function, and their dysregulation is linked to a wide range of human diseases, including metabolic disorders, cardiovascular disease, and neurodegeneration. The SPT complex is also a hub for regulatory inputs, integrating nutrient status and stress signals to control sphingolipid flux. Understanding its structure, assembly, and regulation provides insights into basic cell biology and offers potential therapeutic targets for diseases such as ischemic cardiomyopathy, macular degeneration, and asthma.
• Catalyzes the committed step in sphingolipid biosynthesis, affecting all downstream sphingolipids including ceramides and sphingosine-1-phosphate.
• SPTLC3 is essential for mitochondrial complex I activity and contributes to ischemic cardiomyopathy.
• SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis.
• The complex localizes to ER-mitochondria contact sites, linking lipid synthesis to mitochondrial metabolism.
• Dysregulation of SPT components is implicated in macular disease and peripheral neuropathy.
• Sphingolipid metabolism controlled by SPT influences asthma pathogenesis.
• SPT complex activity affects regulated exocytosis in cytotoxic lymphocytes.
• Regulatory subunits ORMDL1/2/3 and SPTSSA/SPTSSB fine-tune SPT activity in response to cellular needs.
• The SPT complex is a potential therapeutic target for metabolic and cardiovascular diseases.
• CRISPR-based models enable precise dissection of SPT subunit functions in health and disease.
Core Biology of the serine palmitoyltransferase complex
What Happens During serine palmitoyltransferase complex?
In simple terms: The SPT complex starts the production of sphingolipids by joining two molecules together.
The serine palmitoyltransferase complex catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the first sphingoid base in sphingolipid biosynthesis. This reaction is the rate-limiting step for all sphingolipid production. In eukaryotes, the complex is embedded in the ER membrane, where it receives substrates and releases 3-ketosphinganine for further processing. The activity of the complex is tightly regulated by its subunits and interacting proteins.
Catalytic Mechanism and Substrate Specificity
In simple terms: The enzyme uses a cofactor to chemically link serine and palmitoyl-CoA.
The catalytic subunits SPTLC1, SPTLC2, and SPTLC3 form the active site. SPTLC2 and SPTLC3 contain a pyridoxal 5'-phosphate (PLP) cofactor that facilitates the condensation reaction between L-serine and palmitoyl-CoA. SPTLC1 is essential for structural integrity and activity. The substrate specificity can be influenced by the subunit composition; for example, SPTLC3 alters substrate preference and is linked to specific sphingolipid species.
Structure and Composition of serine palmitoyltransferase complex
In simple terms: The complex is made of different proteins that work together like a machine.
The eukaryotic SPT complex is a multiprotein assembly composed of catalytic subunits (SPTLC1, SPTLC2, SPTLC3 in humans; LCB1 and LCB2 in S. cerevisiae) and regulatory subunits. Regulatory components include activators such as SPTSSA and SPTSSB (TSC3 in S. cerevisiae) and negative regulators ORMDL1, ORMDL2, and ORMDL3 (ORM1/2 in S. cerevisiae). The complex is localized to the endoplasmic reticulum membrane, and recent studies show it also assembles at ER-mitochondria contact sites. The bacterial enzyme is a cytoplasmic homodimer, contrasting with the eukaryotic multiprotein complex.
Assembly and Localization
In simple terms: The complex is put together in the ER membrane and can move to contact sites with mitochondria.
The SPT complex assembles in the ER membrane, where catalytic and regulatory subunits come together. The activator subunits SPTSSA/SPTSSB promote complex formation and activity, while ORMDL proteins inhibit it. The complex has been shown to localize at ER-mitochondria contact sites, suggesting a role in inter-organelle communication and mitochondrial function. This localization may facilitate the channeling of sphingolipid precursors to mitochondria and influence mitochondrial activity.
Regulation of SPT Complex Activity
In simple terms: The activity of the complex is turned up or down by other proteins and cellular signals.
SPT complex activity is regulated by its subunits and interacting proteins. ORMDL1/2/3 act as negative regulators, while SPTSSA/SPTSSB act as positive regulators. The complex is also subject to feedback regulation by sphingolipid levels. Additionally, SPTLC3 expression and activity are linked to metabolic states, such as hepatic gluconeogenesis, and to mitochondrial function. The assembly at ER-mitochondria contact sites may provide a mechanism for integrating lipid synthesis with cellular energy status.
Key Genes Involved in GO:0017059 serine palmitoyltransferase complex
The following genes encode subunits and regulators of the serine palmitoyltransferase complex, and their roles are supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPTLC1 | Catalytic subunit, essential for SPT complex integrity and activity | Mutations linked to hereditary sensory and autonomic neuropathy; target for knockout studies |
| SPTLC2 | Catalytic subunit containing PLP cofactor, main catalytic activity | Key for sphingolipid biosynthesis; knockout causes embryonic lethality in mice |
| SPTLC3 | Catalytic subunit, alters substrate specificity and sphingolipid composition | Essential for mitochondrial complex I activity; regulates gluconeogenesis |
| SPTSSA | Activator subunit, promotes SPT activity | Regulates sphingolipid flux; potential target for metabolic diseases |
| SPTSSB | Activator subunit, promotes SPT activity | Modulates SPT complex assembly and function |
| ORMDL1 | Negative regulator of SPT complex | Involved in sphingolipid homeostasis; linked to asthma and immune regulation |
| ORMDL2 | Negative regulator of SPT complex | Modulates SPT activity in response to sphingolipid levels |
| ORMDL3 | Negative regulator of SPT complex | Associated with asthma susceptibility and immune cell function |
| LCB1 | Yeast homolog of SPTLC1, catalytic subunit | Model organism studies of sphingolipid biosynthesis |
| LCB2 | Yeast homolog of SPTLC2, catalytic subunit | Model organism studies of sphingolipid biosynthesis |
| TSC3 | Yeast activator of SPT complex | Regulates SPT activity in yeast |
| ORM1 | Yeast negative regulator of SPT complex | Involved in sphingolipid homeostasis |
| ORM2 | Yeast negative regulator of SPT complex | Involved in sphingolipid homeostasis |
| SAC1 | Yeast phosphatidylinositol phosphatase, part of SPOTS complex | Regulates sphingolipid metabolism and ER function |
| SPTLC3 (human) | Regulates plasma membrane sphingolipid composition | Linked to hepatic gluconeogenesis and ischemic cardiomyopathy |
| ORMDL3 (human) | Negative regulator, asthma susceptibility gene | Target for asthma research and therapy |
| SPTSSA (human) | Activator subunit, enhances SPT activity | Potential therapeutic target for sphingolipid disorders |
How Is serine palmitoyltransferase complex Regulated?
The serine palmitoyltransferase complex is regulated at multiple levels. The ORMDL proteins (ORMDL1/2/3 in humans, ORM1/2 in yeast) act as negative regulators, while SPTSSA/SPTSSB (TSC3 in yeast) act as positive regulators. Sphingolipid levels feedback to modulate SPT activity, ensuring homeostasis. Additionally, SPTLC3 expression is linked to metabolic states such as hepatic gluconeogenesis and mitochondrial function. The assembly of the complex at ER-mitochondria contact sites may integrate lipid synthesis with cellular energy status and mitochondrial activity.
serine palmitoyltransferase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPTLC3 | Ischemic cardiomyopathy; hepatic gluconeogenesis | Cardiomyocyte-specific knockout or overexpression in mice |
| SPTLC1 | Hereditary sensory and autonomic neuropathy | Patient-derived iPSCs with point mutations |
| SPTLC2 | Hereditary sensory and autonomic neuropathy | Knock-in mouse models with patient mutations |
| ORMDL3 | Asthma susceptibility | Airway epithelial cell knockout or overexpression |
| SPTSSA | Sphingolipid disorders | Liver-specific knockout or overexpression |
SPT Complex in Cardiovascular and Metabolic Disease
SPTLC3 is essential for mitochondrial complex I activity and contributes to ischemic cardiomyopathy. It also regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis, linking SPT activity to glucose metabolism. These findings suggest that SPT complex components are potential therapeutic targets for cardiovascular and metabolic disorders.
SPT Complex in Neurodegeneration and Macular Disease
Dysregulation of serine and lipid metabolism, including SPT complex function, is implicated in macular disease and peripheral neuropathy. Mutations in SPTLC1 and SPTLC2 cause hereditary sensory and autonomic neuropathy, highlighting the importance of SPT complex in neuronal health.
SPT Complex in Asthma and Immune Function
ORMDL3, a negative regulator of the SPT complex, is associated with asthma susceptibility. Sphingolipid metabolism controlled by SPT also affects regulated exocytosis in cytotoxic lymphocytes, indicating a role in immune cell function.
From serine palmitoyltransferase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of SPTLC3 in mitochondrial function? | SPTLC3 knockout and overexpression in cardiomyocytes |
| How does SPTLC3 regulate gluconeogenesis? | Liver-specific SPTLC3 knockout or overexpression in mice |
| What is the impact of ORMDL3 on asthma? | ORMDL3 knockout or transgenic mice in asthma models |
| How do SPTLC1 mutations cause neuropathy? | Knock-in mice expressing mutant SPTLC1 |
| What is the function of SPTSSA in sphingolipid homeostasis? | SPTSSA knockout or overexpression cell lines |
| How does SPT complex localize to ER-mitochondria contact sites? | Tagged knock-in of SPT subunits for imaging |
How to Study the serine palmitoyltransferase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Study SPT subunit roles in cells and mice |
| Point mutation knock-in | Effect of specific mutations | Model hereditary sensory neuropathy |
| Overexpression | Gain of function | Assess SPTLC3 in gluconeogenesis |
| Lipidomics | Sphingolipid species quantification | Measure SPT activity and pathway flux |
| Co-immunoprecipitation | Protein-protein interactions | Identify SPT complex components |
| Fluorescence microscopy | Subcellular localization | Visualize SPT at ER-mitochondria contacts |
| RNA-seq | Transcriptome changes | Identify downstream effects of SPT manipulation |
| Proteomics | Protein abundance and modifications | Study SPT complex regulation |
Genetic and Biochemical Approaches
CRISPR-Cas9 knockout, point mutation, and knock-in models are used to dissect SPT subunit functions. Biochemical assays measure SPT activity using radiolabeled serine and palmitoyl-CoA. Co-immunoprecipitation and mass spectrometry identify complex components and interactions.
Imaging and Localization Studies
Fluorescence microscopy and live-cell imaging of tagged SPT subunits reveal localization to the ER and ER-mitochondria contact sites. Super-resolution microscopy can resolve complex assembly and dynamics.
Lipidomics and Metabolomics
Mass spectrometry-based lipidomics quantifies sphingolipid species in cells and tissues, providing readouts of SPT complex activity. Metabolomics can assess flux through the sphingolipid pathway.
Transcriptomics and Proteomics
RNA-seq and proteomics reveal changes in gene expression and protein abundance upon SPT complex manipulation. These approaches identify downstream pathways affected by SPT activity.
How CRISPR Can Be Used to Study GO:0017059 serine palmitoyltransferase complex
Knockout
CRISPR-Cas9 knockout of SPTLC3 in cardiomyocytes revealed its essential role in mitochondrial complex I activity and ischemic cardiomyopathy. Knockout of SPT subunits in cell lines is used to study sphingolipid biosynthesis and cellular stress responses.
Point Mutation
Point mutations in SPTLC1 and SPTLC2 identified in patients with hereditary sensory neuropathy can be introduced into cells or mice using CRISPR to model the disease and study molecular mechanisms.
Knock-in
Knock-in of tagged SPT subunits (e.g., GFP or HA) allows visualization and purification of the complex for interaction and localization studies, including at ER-mitochondria contact sites.
Overexpression
Overexpression of SPTLC3 in liver cells or mice enhances gluconeogenesis and alters plasma membrane sphingolipid composition, providing insights into metabolic regulation.
How EDITGENE Supports serine palmitoyltransferase complex Research
Researchers studying serine palmitoyltransferase complex-related genes often need to determine whether a candidate gene is causally involved in sphingolipid metabolism, organelle function, or disease. Precise genetic models are essential to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for serine palmitoyltransferase complex research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SPTLC1 Knockout HEK293 Cell Line | EDJ-KQ1728 | Human | 10558 | Details Get a Quote |
| SPTLC2 Knockout HEK293 Cell Line | EDJ-KQ1729 | Human | 9517 | Details Get a Quote |
| SPTLC3 Knockout HEK293 Cell Line | EDJ-KQ1731 | Human | 55304 | Details Get a Quote |
| ORMDL2 Knockout HEK293 Cell Line | EDJ-KQ8980 | Human | 29095 | Details Get a Quote |
| ORMDL3 Knockout HEK293 Cell Line | EDJ-KQ10598 | Human | 94103 | Details Get a Quote |
| ORMDL1 Knockout HEK293 Cell Line | EDJ-KQ11286 | Human | 94101 | Details Get a Quote |
| SPTSSB Knockout HEK293 Cell Line | EDJ-KQ15506 | Human | 165679 | Details Get a Quote |
| SPTLC2 Knockout HCT 116 Cell Line | EDJ-KQ20223 | Human | 9517 | Details Get a Quote |
| SPTLC1 Knockout A-549 Cell Line | EDJ-KQ21570 | Human | 10558 | Details Get a Quote |
| SPTLC1 Knockout HCT 116 Cell Line | EDJ-KQ21571 | Human | 10558 | Details Get a Quote |
| SPTLC1 Knockout HeLa Cell Line | EDJ-KQ21572 | Human | 10558 | Details Get a Quote |
| SPTLC2 Knockout A-549 Cell Line | EDJ-KQ21573 | Human | 9517 | Details Get a Quote |
| SPTLC2 Knockout HeLa Cell Line | EDJ-KQ21574 | Human | 9517 | Details Get a Quote |
| SPTLC3 Knockout HeLa Cell Line | EDJ-KQ21575 | Human | 55304 | Details Get a Quote |
| ORMDL2 Knockout A-549 Cell Line | EDJ-KQ35405 | Human | 29095 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About serine palmitoyltransferase complex
What is the serine palmitoyltransferase complex?
The serine palmitoyltransferase (SPT) complex is a protein complex that catalyzes the first and rate-limiting step of sphingolipid biosynthesis, condensing L-serine with palmitoyl-CoA to form 3-ketosphinganine.
What genes are involved in the serine palmitoyltransferase complex?
Key genes include SPTLC1, SPTLC2, SPTLC3 (catalytic subunits), SPTSSA and SPTSSB (activators), and ORMDL1, ORMDL2, ORMDL3 (negative regulators) in humans.
Where is the serine palmitoyltransferase complex located?
In eukaryotes, the complex is localized to the endoplasmic reticulum membrane and also assembles at ER-mitochondria contact sites.
What is the function of GO:0017059?
GO:0017059 describes the serine palmitoyltransferase complex, which catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the starting point for all sphingolipids.
How is the serine palmitoyltransferase complex regulated?
It is regulated by activator subunits (SPTSSA/SPTSSB) and negative regulators (ORMDL1/2/3), as well as feedback from sphingolipid levels.
What diseases are associated with the serine palmitoyltransferase complex?
Mutations in SPTLC1 and SPTLC2 cause hereditary sensory and autonomic neuropathy; SPTLC3 is linked to ischemic cardiomyopathy and gluconeogenesis; ORMDL3 is associated with asthma.
What is the role of SPTLC3 in the SPT complex?
SPTLC3 is a catalytic subunit that alters substrate specificity and is essential for mitochondrial complex I activity and hepatic gluconeogenesis.
How can I study the serine palmitoyltransferase complex using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect subunit functions and disease mechanisms.
What are the synonyms for serine palmitoyltransferase complex?
Synonyms include serine C-palmitoyltransferase complex, SPT, SPOTS complex, and Orm1/2, Tsc3 and Sac1 complex.
Why is the serine palmitoyltransferase complex important for cell biology?
It controls the flux of all sphingolipids, which are essential for membrane structure, signaling, and organelle function, and its dysregulation leads to various diseases.
Conclusion
The serine palmitoyltransferase complex (GO:0017059) is a central enzyme in sphingolipid biosynthesis, with critical roles in membrane biology, metabolism, and disease. Its multi-subunit composition and regulatory mechanisms make it a fascinating subject for both basic and translational research. Advances in CRISPR-based models and lipidomics continue to uncover new insights into its function and therapeutic potential.
References
- 1. Kovilakath A et al.. 2024. SPTLC3 Is Essential for Complex I Activity and Contributes to Ischemic Cardiomyopathy.. Circulation 150(8):622-641 PMID: 38660786
- 2. Montefusco D et al.. 2024. SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis.. Cell Rep 43(12):115054 PMID: 39661520
- 3. Wattenberg BW. 2021. Kicking off sphingolipid biosynthesis: structures of the serine palmitoyltransferase complex.. Nat Struct Mol Biol 28(3):229-231 PMID: 33558763
- 4. Aaltonen MJ et al.. 2022. Serine palmitoyltransferase assembles at ER-mitochondria contact sites.. Life Sci Alliance 5(2) PMID: 34785538
- 5. Worgall TS. 2022. Sphingolipids and Asthma.. Adv Exp Med Biol 1372:145-155 PMID: 35503179
- 7. Kalinichenko A et al.. 2025. Protein palmitoylation and sphingolipid metabolism control regulated exocytosis in cytotoxic lymphocytes.. Sci Immunol 10(112):eado3825 PMID: 41105755
- 8. Gantner ML et al.. 2019. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy.. N Engl J Med 381(15):1422-1433 PMID: 31509666
